FUSN insider transaction filings
Fusion Pharmaceuticals Inc. — 14 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2024-06-04. Screen FUSN transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for FUSN between 2026-06-11 and 2026-09-09. The table below lists the most recent filings on record.
Recent Form 4 filings — Fusion Pharmaceuticals Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-06-04 | 4 | Bitetti Teresa Marie — Director | Disposition to issuer (D): 34,000 (derivative) | EDGAR |
| 2024-06-04 | 4 | Valliant John — Chief Executive Officer, Director | Disposition to issuer (D): 318,147 · Disposition to issuer (D): 533,095 (derivative) · Disposition to issuer (D): 270,300 (derivative) · Disposition to issuer (D): 606,721 (derivative) · Disposition to issuer (D): 173,528 (derivative) · Disposition to issuer (D): 206,541 (derivative) · +6 more | EDGAR |
| 2024-06-04 | 4 | Lee Philina — Director | Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) | EDGAR |
| 2024-06-04 | 4 | Rawat Mohit — President & CBO | Disposition to issuer (D): 21,699 · Disposition to issuer (D): 257,000 (derivative) · Disposition to issuer (D): 77,900 (derivative) · Disposition to issuer (D): 300,000 (derivative) · Disposition to issuer (D): 135,500 (derivative) · Disposition to issuer (D): 81,300 (derivative) | EDGAR |
| 2024-06-04 | 4 | Bobilev Dmitri — Chief Medical Officer | Disposition to issuer (D): 550,000 (derivative) · Disposition to issuer (D): 151,700 (derivative) · Disposition to issuer (D): 91,000 (derivative) | EDGAR |
| 2024-06-04 | 4 | Bender Jeremy — Director | Disposition to issuer (D): 34,000 (derivative) | EDGAR |
| 2024-06-04 | 4 | Burak Eric — Chief Technology Officer | Disposition to issuer (D): 38,490 · Disposition to issuer (D): 159,928 (derivative) · Disposition to issuer (D): 81,090 (derivative) · Disposition to issuer (D): 72,340 (derivative) · Disposition to issuer (D): 38,561 (derivative) · Disposition to issuer (D): 44,754 (derivative) · +9 more | EDGAR |
| 2024-06-04 | 4 | Bergstrom Donald A — Director | Disposition to issuer (D): 34,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) | EDGAR |
| 2024-06-04 | 4 | GANNON STEVEN — Director | Disposition to issuer (D): 56,400 · Disposition to issuer (D): 141,011 (derivative) · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) | EDGAR |
| 2024-06-04 | 4 | Crowley John J — Chief Financial Officer | Disposition to issuer (D): 10,410 · Disposition to issuer (D): 38,561 (derivative) · Disposition to issuer (D): 26,972 (derivative) · Disposition to issuer (D): 60,852 (derivative) · Disposition to issuer (D): 138,000 (derivative) · Disposition to issuer (D): 167,000 (derivative) · +4 more | EDGAR |
| 2024-06-04 | 4 | Meek David D. — Director | Disposition to issuer (D): 34,000 (derivative) | EDGAR |
| 2024-06-04 | 4 | Leamon Christopher P — Chief Scientific Officer | Disposition to issuer (D): 11,957 · Disposition to issuer (D): 218,000 (derivative) · Disposition to issuer (D): 250,000 (derivative) · Disposition to issuer (D): 106,100 (derivative) · Disposition to issuer (D): 63,700 (derivative) | EDGAR |
| 2024-06-04 | 4 | Duncan Barbara Gayle — Director | Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) | EDGAR |
| 2024-06-04 | 4 | CAGNONI PABLO J — Director | Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 141,011 (derivative) | EDGAR |
Recent 8-K events — Fusion Pharmaceuticals Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-06-04 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-05-31 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-05-29 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=FUSN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →